Target regimen profiles for tuberculosis treatment
Christian Lienhardt,Kelly E Dooley,Payam Nahid,Charles Wells,Theresa S Ryckman,Emily A Kendall,Gerry Davies,Grania Brigden,Gavin Churchyard,Daniela Maria Cirillo,Eugenia Di Meco,Ramya Gopinath,Carole Mitnick,Cherise Scott,Farhana Amanullah,Cathy Bansbach,Martin Boeree,Michael Campbell,Francesca Conradie,Angela Crook,Charles L Daley,Keertan Dheda,Andreas Diacon,Agnes Gebhard,Debra Hanna,Norbert Heinrich,Anneke Hesseling,David Holtzman,Mathilde Jachym,Peter Kim,Christoph Lange,Lindsay McKenna,Graeme Meintjes,Norbert Ndjeka,Nguyen Viet Nhung,Bern-Thomas Nyang'wa,Nicholas I Paton,Raghuram Rao,Michael Rich,Rada Savic,Ingrid Schoeman,Boitumelo Semete Makokotlela,Mel Spigelman,Eugene Sun,Elin Svensson,Phumeza Tisile,Francis Varaine,Andrew Vernon,Mukadi Ya Diul,Tereza Kasaeva,Matteo Zignol,Medea Gegia,Fuad Mirzayev,Samuel G Schumacher
DOI: https://doi.org/10.2471/BLT.24.291881
2024-08-01
Abstract:Simpler, shorter, safer and more effective treatments for tuberculosis that are easily accessible to all people with tuberculosis are desperately needed. In 2016, the World Health Organization (WHO) developed target regimen profiles for the treatment of tuberculosis to make drug developers aware of both the important features of treatment regimens, and patient and programmatic needs at the country level. In view of recent ground-breaking advances in tuberculosis treatment, WHO has revised and updated these regimen profiles. We used a similar process as for the 2016 profiles, including a baseline treatment landscape analysis, an initial stakeholder survey, modelling studies estimating the impact and cost-effectiveness of novel tuberculosis treatment regimens, and an extensive stakeholder consultation. We developed target regimen profiles for the treatment of rifampicin-susceptible and rifampicin-resistant tuberculosis, as well as a pan-tuberculosis regimen that would be appropriate for patients with any type of tuberculosis. We describe the revised target regimen profile characteristics, with specific minimal and optimal targets to be met, rationale and justification, and aspects relevant to all target regimen profiles (drug susceptibility testing, adherence and forgiveness, treatment strategies, post-tuberculosis lung disease, and cost and access considerations). We discuss the trade-offs of proposed characteristics for decision-making at developmental or operational levels. We expect that, following these target regimen profile revisions, tuberculosis treatment developers will produce regimens that are quality-assured, affordable and widely available, and that meet the needs of affected populations.